Rheumatology.net

Rheumatology Xagena

Xagena Mappa
Medical Meeting
Pneumobase.it
Ematobase.it

Patients with ankylosing spondylitis: effects of aerobic training


A study has evaluated the effects of aerobic exercise in patients with ankylosing spondylitis ( AS ).

Seventy patients classified with ankylosing spondylitis by the modified New York criteria were included.

The patients were randomly assigned into 2 groups. The intervention group ( IG ) performed 50 min of walking followed by stretching exercises 3 times a week for 12 weeks.
The control group ( CG ) performed only stretching exercises.

The outcome measurements were the Bath indexes [ Bath AS Functional Index ( BASFI ), Bath AS Disease Activity Index ( BASDAI ), and Bath AS Metrology Index ( BASMI ) ], Health Assessment Questionnaire for the Spondyloarthropathies ( HAQ-S ), AS Disease Activity Score ( ASDAS ), the 6-min walk test ( 6MWT ), chest expansion, and the Medical Outcomes Study Short Form-36.

Aerobic capacity was assessed by ergospirometry on a treadmill.

Assessments were performed immediately before randomization and after 6, 12, and 24 weeks.

Thirty-five patients were randomized to the intervention group and 35 to the control group.

There was significant improvement in the BASFI, HAQ-S, BASMI, BASDAI, and ASDAS in both groups ( p less than 0.05 ), but did not differ between groups.

There was a significant increase in the walking distance in the 6MWT in the intervention group compared with control group ( p less than 0.001 ).

The intervention group showed significant improvement in cardiopulmonary capacity compared with control group.

Cholesterol and triglyceride levels did not change in either group.

In conclusion, in patients with ankylosing spondylitis, aerobic training improved walking distance and aerobic capacity.
Aerobic training did not provide additional benefits in functional capacity, mobility, disease activity, quality of life, and lipid levels when compared with stretching exercises alone. ( Xagena )

Jennings F et al, J Rheumatol 2015;42:2347-2353

XagenaMedicine_2015



Indietro